These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38852648)

  • 1. CAR-T therapy for ovarian cancer: Recent advances and future directions.
    Xin Q; Chen Y; Sun X; Li R; Wu Y; Huang X
    Biochem Pharmacol; 2024 Jun; 226():116349. PubMed ID: 38852648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
    Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
    Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
    Zhu X; Cai H; Zhao L; Ning L; Lang J
    Oncotarget; 2017 Sep; 8(38):64607-64621. PubMed ID: 28969098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
    Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
    J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
    Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
    Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
    Zhang XW; Wu YS; Xu TM; Cui MH
    Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
    Li H; Song W; Li Z; Zhang M
    Front Immunol; 2022; 13():992232. PubMed ID: 36353643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
    Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
    Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
    Date V; Nair S
    Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
    Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
    Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.
    Schepisi G; Casadei C; Toma I; Poti G; Iaia ML; Farolfi A; Conteduca V; Lolli C; Ravaglia G; Brighi N; Altavilla A; Martinelli G; De Giorgi U
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy.
    Zhang Y; Yang J; Zhang T; Gu H
    Front Bioeng Biotechnol; 2023; 11():1211687. PubMed ID: 37388769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.
    Yan W; Hu H; Tang B
    Onco Targets Ther; 2019; 12():8015-8022. PubMed ID: 31686857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.